bioMérieux announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel.
Invisible Sentinel®, a bioMérieux, Inc. company, obtains the first AOAC® approval for the detection of pathogenic Aspergillus spp. in cannabis.
bioMérieux receives the first AOAC® validation approval for cannabis and hemp.
Please be advised that bioMérieux Inc. sites in Durham, NC, St. Louis, MO, and Lombard, IL will be closed on Monday, January 18th, 2021 in observance of the upcoming holiday.
The Assay couples the advantages of real-time PCR technology with a streamlined environmental sampling protocol, providing rapid and accurate results with superior specificity.
These approvals add to bioMérieux’s already vast AOAC approved portfolio across their pathogen and quality indicator suite of solutions, and demonstrates a long-standing commitment to robust, sound, and validated science.
The innovative software-as-a-service reflects growing capabilities and global mission for antimicrobial stewardship and surveillance.
Please be advised that in observance of upcoming holidays, bioMérieux, Inc. sites in Durham, NC, St. Louis, MO, Louisville, KY, and Lombard, IL will be closed on: Thursday/Friday November 26/27, 2020 Thursday/Friday December 24/25, 2020 Friday January 1, 2021 We encourage you to place orders with the following dates in mind.
Predictive Diagnostics uses traditional core microbiology solutions alongside data science, sequencing applications and predictive modeling to help move food producers from being reactive to being proactive.
Due to the significant economic and social consequences presented by the COVID-19 pandemic, bioMérieux has decided to distribute 50% of its 2019 dividend as corporate philanthropy to support charitable initiatives around the world.
